

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>El-Hibri Fuad</u> (Last) (First) (Middle) 400 PROFESSIONAL DRIVE, SUITE 400 (Street) GAITHERSBURG MD 20879 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Emergent BioSolutions Inc. [EBS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chairman
	3. Date of Earliest Transaction (Month/Day/Year) 02/26/2020	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/26/2020		F		2,365	D	\$59.91 ⁽¹⁾	1,482,663	D	
Common Stock	02/26/2020		M		6,429	A	⁽²⁾	1,489,092	D	
Common Stock	02/26/2020		F		2,530	D	\$59.91	1,486,562	D	
Common Stock	02/26/2020		S ⁽³⁾		13,619	D	\$58.7 ⁽⁴⁾	1,472,943	D	
Common Stock	02/27/2020		M		9,794	A	⁽²⁾	1,482,737	D	
Common Stock	02/27/2020		F		3,854	D	\$58.42	1,478,883	D	
Common Stock	02/27/2020		S ⁽³⁾		9,837	D	\$56.97 ⁽⁵⁾	1,469,046	D	
Common Stock								4,344,250 ⁽⁶⁾	I	By Intervac, L.L.C.
Common Stock								1,524,155 ⁽⁷⁾	I	By Biovac, L.L.C.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Unit	⁽²⁾	02/26/2020		M		6,429		⁽⁸⁾	⁽⁸⁾	Common Stock	6,429	\$0.00	47,774	D	
Restricted Stock Unit	⁽²⁾	02/27/2020		M		9,794		⁽⁹⁾	⁽⁹⁾	Common Stock	9,794	\$0.00	37,980	D	

Explanation of Responses:

- Represents a withholding of shares by Emergent Biosolutions Inc. to satisfy tax withholding obligations on the vesting of restricted stock units pursuant to award granted February 26, 2019, which was inadvertently not reported on a Form 4 filed on February 27, 2020.
- Restricted stock units convert into common stock on a one-for-one basis.
- All sales listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934.
- The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from \$57.38 to \$60.39.
- The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from \$56.25 to \$58.08.
- Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
- Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C., which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
- On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.

9. On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.

Remarks:

/s/ Carl A. Valenstein, attorney-
in-fact 02/28/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.